In addition, the research of Konopka et al. shows that the existence of CEBPA is positively correlated with the adverse clinical outcomes of patients, and the upregulation of CEBPA expression has a negative impact on the survival rate of patients with ovarian cancer, which can be an effective molecular marker for predicting prognosis (24). This evidence concerns the gene CEBPA and ovarian cancer.